Document is current
Any future updates will be listed below
-
Authors
Tisseverasinghe, Steven
Tolba, Marwan https://orcid.org/0000-0003-2812-7348
Bahoric, Boris
Saad, Fred https://orcid.org/0000-0003-2986-5617
Niazi, Tamim
- License Information
-
More Information
Article History
First Online: 5 June 2025
Competing interests
: S.T. receives honoraria and consulting fees from Tolmar, AbbVie, Knight, Bayer, Janssen and Sumitomo pharma. M.T. receives honoraria and consulting fees from AbbVie, Tersera and Knight. F.S. has grants/contracts with Janssen, Bayer, Merck, Pfizer, Astellas, BMS, Novartis, Sanofi and AstraZeneca; receives consulting fees from Janssen, Bayer, Astellas, Novartis, Sanofi, AstraZeneca, Merck, Pfizer, Somitomo and Tolmar; and receives honoraria from Janssen, Bayer, Somitomo, Astellas, Novartis, Sanofi, AstraZeneca, Merck, Pfizer and Tolmar. T.N. has grants/contracts with Bayer, Jansen, Astellas, Tersera and Sanofi Canada; receives consulting fees from AbbVie, Astellas, Jansen, Tersera, Tolmar, Bayer, AAA, Pfizer, Knight, AstraZeneca and Sumitomo pharma; receives support for attending meetings/travel from Jansen, Tolmar, Knight and Bayer; and is the chair of the Quebec GU Radiation oncology group and co-chair of the Canadian GU radiation oncology group. B.B. declares no competing interests.
